| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/25/2002 | WO2002032888A1 Substituted dipeptides as growth hormone secretagogues |
| 04/25/2002 | WO2002032883A1 Novel 4-benzyloxyphenyl derivative and use thereof |
| 04/25/2002 | WO2002032881A1 Novel remedies or preventives for angiostenosis |
| 04/25/2002 | WO2002032879A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 04/25/2002 | WO2002032874A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 04/25/2002 | WO2002032872A1 Nitrogenous aromatic ring compounds |
| 04/25/2002 | WO2002032869A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 04/25/2002 | WO2002032868A2 2-substituted heterocyclic compounds and their use in treating multidrug resistance |
| 04/25/2002 | WO2002032864A1 Pharmaceutically active sulfanilide derivatives |
| 04/25/2002 | WO2002032861A2 Orally active salts with tyrosine kinase activity |
| 04/25/2002 | WO2002032858A1 Cycloalkylfluorosulfonamide derivatives |
| 04/25/2002 | WO2002032842A2 Compounds with high monoamine transporter affinity |
| 04/25/2002 | WO2002032461A2 Protein c or activated protein c-like molecules |
| 04/25/2002 | WO2002032458A2 System and methods for optimized drug delivery and progression of diseased and normal cells |
| 04/25/2002 | WO2002032447A2 Cell damage inhibitor |
| 04/25/2002 | WO2002032445A2 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | WO2002032444A1 Novel medicinal herbal composition for treating liver diseases and hiv |
| 04/25/2002 | WO2002032436A1 Use of bioactive fraction from cow urine distillate ('go mutra') as a bio-enhancer of anti-infective, anti-cancer agents and nutrients |
| 04/25/2002 | WO2002032435A2 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 04/25/2002 | WO2002032432A1 Use of antiprogestins for the induction of apoptosis in a cell |
| 04/25/2002 | WO2002032423A1 Pharmaceutical compositions containing oxapenem-3-carboxylic acids |
| 04/25/2002 | WO2002032422A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | WO2002032419A2 Methods for modulating bladder function |
| 04/25/2002 | WO2002032418A1 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis |
| 04/25/2002 | WO2002032411A2 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | WO2002032401A1 Amifostine powder injection and its method of process |
| 04/25/2002 | WO2002032397A2 Electroprocessing in drug delivery and cell encapsulation |
| 04/25/2002 | WO2002032375A2 Uses of monoclonal antibody 8h9 |
| 04/25/2002 | WO2002022112A9 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 04/25/2002 | WO2001097810A3 Use of therapeutic benzamide derivatives |
| 04/25/2002 | WO2001096366A3 Dipeptide inhibitors for the blood-clotting factor xa |
| 04/25/2002 | WO2001089500A3 Agents and methods for increasing brain chaperonin levels |
| 04/25/2002 | WO2001088136A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 04/25/2002 | WO2001083740A3 Splice-region antisense composition and method |
| 04/25/2002 | WO2001081333A3 Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes |
| 04/25/2002 | WO2001078754A3 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof |
| 04/25/2002 | WO2001078698A3 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain |
| 04/25/2002 | WO2001072831A3 Immunoregulator |
| 04/25/2002 | WO2001066110A3 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS |
| 04/25/2002 | WO2001062300A3 Caspase activated prodrugs therapy |
| 04/25/2002 | WO2001061010A3 GTPASE activating proteins |
| 04/25/2002 | WO2001060174A3 Weight loss induced by reduction in neuropeptide y level |
| 04/25/2002 | WO2001057240A3 Interaction of nmda receptor with protein tyrosine phosphatase |
| 04/25/2002 | WO2001056552A3 Farnesyl protein transferase inhibitors for treating breast cancer |
| 04/25/2002 | WO2001047533A3 INHIBITION OF GSK-3$g(b) |
| 04/25/2002 | WO2001043753A3 Combination of ginseng and ginkgo to improve cognitive skills |
| 04/25/2002 | WO2001002369A3 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 04/25/2002 | US20020049335 DNA alkylating compounds such as 1-(tert-butyloxycarbonyl) -4-hydroxy-3(((methane-sulfonyl)oxy)methyl)-2,3-dihydroindole |
| 04/25/2002 | US20020049329 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them |
| 04/25/2002 | US20020049326 Benzosulfones and related compositions and methods |
| 04/25/2002 | US20020049325 Calcium channel blockers |
| 04/25/2002 | US20020049324 Topoisomerase inhibitors |
| 04/25/2002 | US20020049313 Method for introducing foreign material into higher eukaryotic cells |
| 04/25/2002 | US20020049301 For therapy of cancer, diabetes, obesity, diseases of the central nervous system, inflammatory disorders, autoimmune dieseases cardiovascular diseases, for generating antibodies |
| 04/25/2002 | US20020049254 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 04/25/2002 | US20020049253 Structural or functional components of the creatine kinase/ phosphocreatine system sufficient to prevent, reduce or ameliorate skin damage or skin aging |
| 04/25/2002 | US20020049251 Wedelolactone and its synthesis for treating neurodegenerative diseases |
| 04/25/2002 | US20020049250 PPAR receptor activator compounds for treating cutaneous disorders/afflictions |
| 04/25/2002 | US20020049249 PPAR receptor activator compounds for treating cutaneous disorders/afflictions |
| 04/25/2002 | US20020049248 Alone or in combination for treatment of adult-T-cell leukemia- lymphoma |
| 04/25/2002 | US20020049245 Tumor necrosis factor alpha (TNF-alpha) inhibiting pharmaceuticals |
| 04/25/2002 | US20020049243 Pyrrolidine derivatives |
| 04/25/2002 | US20020049238 Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 04/25/2002 | US20020049234 Inhibitors of factor Xa; for example 3-(4-tert-butylbenzoyl)amino-N-(4-methoxyphenyl)-2-thiophenecarboxamide |
| 04/25/2002 | US20020049233 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 04/25/2002 | US20020049232 Method of treating parkinson's disease |
| 04/25/2002 | US20020049231 S(-)-3-aminothalidomide; treating wide variety of diseases including diabetic retinopathy |
| 04/25/2002 | US20020049226 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis |
| 04/25/2002 | US20020049225 Quinuclidine-substituted aryl compounds for treatment of disease |
| 04/25/2002 | US20020049224 Alpha v integrin receptor antagonists |
| 04/25/2002 | US20020049222 Cyclopentyl modulators of chemokine receptor activity |
| 04/25/2002 | US20020049220 Substituted azoles |
| 04/25/2002 | US20020049215 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
| 04/25/2002 | US20020049214 Aralkyl and aralkylidene heterocyclic lactams and imides as selective agonists and antagonists of serotonin 1 (5-HT1) recepor, used in treating hypertension and all forms of depression |
| 04/25/2002 | US20020049212 Benzimidazole compounds and salts containing piperidine ring are useful in treatment or prevention or medical conditions selected from pain, and inflammatoy diseases; analgesics |
| 04/25/2002 | US20020049211 Combination treatment for depression and anxiety |
| 04/25/2002 | US20020049209 Dopamine D4 ligands for the treatment of novelty-seeking disorders |
| 04/25/2002 | US20020049208 Imidazo[1,2-a]pyrazines for the treatment of neurological disorders |
| 04/25/2002 | US20020049204 1,4-dihydro-benzo(d)oxazin-2-one derivatives useful for treating hormone-dependent neoplastic disease is selected from uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy, carcinomas, and adenocarcinoma |
| 04/25/2002 | US20020049203 CRF receptor antagonists and methods relating thereto |
| 04/25/2002 | US20020049202 Administering halogenated amidino or oxyamidino compound to treat diseases caused by nitric oxide synthase |
| 04/25/2002 | US20020049200 Use of a methylol-containing compound to treat tumors |
| 04/25/2002 | US20020049199 N-linked carbamates and ureas of heterocyclic thioesters |
| 04/25/2002 | US20020049198 Administering to a patient having or at risk of having osteoarthritis, a therapeutically effective amount of an bicyclicaromatic or heteroaromatic compound containing amine and hydroxy groups |
| 04/25/2002 | US20020049196 Hexahydro-pyrazolo-(4,3-c)pyridine derivatives useful for increasing the endogenous production or release of growth hormone in a human or other animal, thus treat or prevent osteoporosis |
| 04/25/2002 | US20020049195 Urea compounds that are muscarinic receptor antagonists and agonists, administering to the mammal the urea compound to treat urinary incontinence, chronic pulmonary obstructive disease, asthma, hyper salivation, blurred vision etc. |
| 04/25/2002 | US20020049194 A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist |
| 04/25/2002 | US20020049193 Inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity. |
| 04/25/2002 | US20020049190 Useful in binding nitric oxide; inhibiting tumor growth |
| 04/25/2002 | US20020049187 2-(azetidin-2-on-1-yl) acetic acid derivatives; treatment of obsessive-compulsive disorder |
| 04/25/2002 | US20020049186 Phenylazophenylacetic acid derivatives; treating inflammatory bowel disease |
| 04/25/2002 | US20020049185 Malonic acid based matrix metalloproteinase inhibitors |
| 04/25/2002 | US20020049183 Phospholipids, espeically phosphatidylethanolamines, covalently bound to physiologically acceptable monomers or polymers. |
| 04/25/2002 | US20020049182 Administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies. |
| 04/25/2002 | US20020049180 KIAA0175 inhibitor is selected from the group consisting of an anti-sense molecule, a ribozyme, an antibody, an antibody fragment, a protein, a polypeptide and a small molecule. |
| 04/25/2002 | US20020049170 Method for reducing toxicity of combined chemotherapies |
| 04/25/2002 | US20020049164 Prodrugs of DP IV-inhibitors |
| 04/25/2002 | US20020049151 Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors |
| 04/25/2002 | US20020048801 Peptide with enzymatic activity; for use as diagnostic tools in detecting cancer and cardiovascular and liver disorders |
| 04/25/2002 | US20020048794 Polypeptides for use in the diagnosis and treatment of skin disorders, cancer, vision and demyelination defects, inflammation, glomerculonephritis, Kaposi's sarcoma, angiogenesis, sarcoidosis, osteoarthritis and aneurysm |